Xiamen Key Laboratory of Cardiovascular Disease, Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Stem Cell Rev Rep. 2022 Dec;18(8):2593-2605. doi: 10.1007/s12015-022-10385-1. Epub 2022 May 8.
Cardiac organoids (COs) are miniaturized and simplified organ structures that can be used in heart development biology, drug screening, disease modeling, and regenerative medicine. This cardiac organoid (CO) model is revolutionizing our perspective on answering major cardiac physiology and pathology issues. Recently, many research groups have reported various methods for modeling the heart in vitro. However, there are differences in methodologies and concepts. In this review, we discuss the recent advances in cardiac organoid technologies derived from human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs), with a focus on the summary of methods for organoid generation. In addition, we introduce CO applications in modeling heart development and cardiovascular diseases and discuss the prospects for and common challenges of CO that still need to be addressed. A detailed understanding of the development of CO will help us design better methods, explore and expand its application in the cardiovascular field.
心脏类器官(COs)是微型化和简化的器官结构,可用于心脏发育生物学、药物筛选、疾病建模和再生医学。这种心脏类器官(CO)模型正在彻底改变我们对回答主要心脏生理学和病理学问题的看法。最近,许多研究小组已经报道了许多在体外模拟心脏的方法。然而,它们在方法和概念上存在差异。在这篇综述中,我们讨论了源自人类胚胎干细胞(hESCs)和人类诱导多能干细胞(hiPSCs)的心脏类器官技术的最新进展,重点总结了类器官生成的方法。此外,我们还介绍了 CO 在心脏发育和心血管疾病建模中的应用,并讨论了 CO 的前景和仍需要解决的共同挑战。详细了解 CO 的发展将有助于我们设计更好的方法,探索并扩展其在心血管领域的应用。